Ndị na-emepụta China Sacubitril Hemicalcium na ndị na-ebu ihe

Sacubitril Hemicalcium

Nkọwa dị mkpirikpi:

Aha API	Ngosipụta	Nkọwapụta	US DMF	EU DMF	CEP
Sacubitril Hemicalcium		N'ime ụlọ

Zitere anyị email

Nkọwa ngwaahịa

Mkpado ngwaahịa

Nkọwa ngwaahịa

沙库比曲半钙盐	Sacubitril Hemicalcium	1369773-39-6	N'ime ụlọ
沙库比曲钠盐		149690-05-1	N'ime ụlọ
LCZ-4		1426129-50-1	N'ime ụlọ
LCZ-7		1012341-48-8	N'ime ụlọ
LCZ-8		1012341-50-2	N'ime ụlọ
LCZ-9		149690-12-0	N'ime ụlọ

ndabere

AHU-377 hemicalcium nnu bụ nnu hemicalcium nke AHU-377. Ọ bụ ihe mgbochi nke neprilysin nwere uru IC50 nke 5 nM [1].

AHU-377 na angiotensin II AT1 antagonist valsartan dere LCZ696 na nha 1: 1 molar. LCZ696 bụ angiotensin receptor neprilysin inhibitor. Ọ nwere ike ibelata ọbara mgbali ma bụrụkwa ọgwụ ọhụrụ maka ọgwụgwọ nkụda obi. AHU-377 bụ pro-ọgwụ, ọ nwere ike gbanwee site enzymatic cleavage nke ethyl ester n'ime arụ ọrụ ụdị LBQ657. A na-akọ na AHU-377 (30 na 100 mg / kg, PO) nwere ike ịkpata mmetụta antihypertensive n'ụzọ dabere na dose na oke DAHI-SS. Ma na DOCA-nnu hypertensive oke, ọ na-egosi mbelata adịghị ike [2, 3].

Ntụaka:
[1] Ksander GM, Ghai RD, deJesus R, Diefenbacher CG, Yuan A, Berry C, Sakane Y, Trapani A. Dicarboxylic acid dipeptide inhibitors endopeptidase inhibitors. J Med Chem. 1995 Mee 12; 38 (10): 1689-700.
[2] Voors AA, Dorhout B, van der Meer P. Ọrụ nwere ike nke valsartan + AHU377 (LCZ696) na ọgwụgwọ nke nkụda obi. Ndị ọkachamara na-enyocha ọgwụ ọjọọ. 2013 Ọgọst; 22 (8): 1041-7 .
[3] Laxminarayan G Hegde, Cecile Yu, Cheruvu Madhavi et al. Ntụnyere arụmọrụ nke AHU-377, onye na-egbochi neprilysin dị ike, n'ụdị oke abụọ nke ọbara mgbali elu dabere na olu. BMC Pharmacology 2011, 11 (Nkwadebe 1):P33.